Compare ResMed Inc. (RMD) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Victoria's Secret & Co — how do they compare? ResMed Inc. trades at $225.25 (market cap $32.61B), while Victoria's Secret & Co trades at $94.36 (market cap $7.48B). The key difference: ResMed Inc. is far larger — about 4.4× Victoria's Secret & Co's market cap, and ResMed Inc. pays a 1.17% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| RMD | VSXY | |
|---|---|---|
Market Cap | $32.61B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $293.73 | $99.97 |
52-Week Low | $182.82 | $21.34 |
Enterprise Value | $31.97B | $10.13B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
VSXY trades at $94.6, down 5.37% today but near its 52-week high, with a bullish technical signal and strong support at $93. The company reported Q1 2026 EPS of $0.60, beating expectations, and shows improving net income margins. Analyst consensus is a Buy with a $91 target, while recent news highlights growth through data-driven marketing and international expansion.
Outlook is positive with earnings momentum and international growth, but risks include high valuation (P/E 37.51) and competitive pressures. Investors may find opportunity in continued execution, though margin sustainability and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
